TGFB1 and idiopathic pulmonary fibrosis: Due to its ability to alter metabolic pathways, to inhibit TGFβ1 signaling, to suppress collagen formation and to promote transdifferentiation of myo- into lipofibroblasts, metformin should be considered as a therapeutic option for IPF patients.